RenovoRx (NASDAQ:RNXT – Get Free Report) and Omnicell (NASDAQ:OMCL – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.
Profitability
This table compares RenovoRx and Omnicell’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| RenovoRx | -621.71% | -135.11% | -101.91% |
| Omnicell | 3.13% | 5.66% | 3.57% |
Institutional & Insider Ownership
3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 97.7% of Omnicell shares are owned by institutional investors. 9.4% of RenovoRx shares are owned by insiders. Comparatively, 2.9% of Omnicell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| RenovoRx | 1 | 0 | 2 | 1 | 2.75 |
| Omnicell | 0 | 2 | 7 | 0 | 2.78 |
RenovoRx presently has a consensus target price of $8.50, indicating a potential upside of 437.97%. Omnicell has a consensus target price of $57.86, indicating a potential upside of 72.19%. Given RenovoRx’s higher possible upside, equities analysts clearly believe RenovoRx is more favorable than Omnicell.
Earnings and Valuation
This table compares RenovoRx and Omnicell”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| RenovoRx | $1.12 million | 63.67 | -$11.17 million | ($0.31) | -5.10 |
| Omnicell | $1.18 billion | 1.29 | $2.05 million | $0.84 | 40.00 |
Omnicell has higher revenue and earnings than RenovoRx. RenovoRx is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
RenovoRx has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.
Summary
Omnicell beats RenovoRx on 10 of the 14 factors compared between the two stocks.
About RenovoRx
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
About Omnicell
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Receive News & Ratings for RenovoRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RenovoRx and related companies with MarketBeat.com's FREE daily email newsletter.
